Dikme Reşat, Aydın Mehmet Salih, Temiz Ebru, Koyuncu İsmail, Işık Mesut
Department of Perfusion Techniques Program, Vocational School of Health Services, Harran University, Şanlıurfa, Turkey.
Department of Cardiovascular Surgery, Faculty of Medicine, Harran University, Şanlıurfa, Turkey.
J Cell Mol Med. 2025 Jun;29(11):e70625. doi: 10.1111/jcmm.70625.
The aim of this study was to determine the gene expression and protein levels of interleukin-33 (IL-33), fetuin A and cytokeratin 18 (CK-18) in the pericardial fluid (PF) and plasma of patients with coronary artery disease (CAD) undergoing coronary artery bypass grafting (CABG). The CAD patients (mean age: 73.4 years) were enrolled. The IL-33, fetuin A, and CK-18 protein levels in pericardial fluid (PF) and plasma of patients with CAD were measured by ELISA, while IL-33 and Fetuin A gene expressions were analysed via quantitative reverse transcription-PCR (qRT-PCR). The IL-33 protein level in PF was significantly higher than plasma (PF: 57.09 ng/L; Plasma: 50.15 ng/L; p < 0.05). Similarly, the fetuin A protein levels were significantly elevated in PF compared to plasma (PF: 1060.53 mg/L; Plasma: 725.85 mg/L; p < 0.05). However, gene expression levels (ΔCt values) for IL-33 and fetuin A were significantly higher in plasma than in PF (p < 0.05). The CK-18 protein levels were comparable between plasma and PF (p > 0.05). Strong positive correlations were observed between CK-18 and IL-33 (r = 0.127, p < 0.001) and between CK-18 and fetuin A (r = 0.096, p < 0.001) in PF. The IL-33, fetuin A, and CK-18 levels in PF are predicted to have the potential to be used as a source of biomarkers for CAD. Although the collection of PF samples requires an invasive procedure, the proximity of PF to the heart tissue makes it a valuable source for understanding cardiac pathophysiology. These findings highlight the potential diagnostic and therapeutic utility of PF biomarkers in patients with CAD.
本研究旨在测定接受冠状动脉旁路移植术（CABG）的冠心病（CAD）患者心包积液（PF）和血浆中白细胞介素-33（IL-33）、胎球蛋白A和细胞角蛋白18（CK-18）的基因表达及蛋白水平。纳入了CAD患者（平均年龄：73.4岁）。采用酶联免疫吸附测定（ELISA）法检测CAD患者心包积液（PF）和血浆中IL-33、胎球蛋白A和CK-18的蛋白水平，同时通过定量逆转录聚合酶链反应（qRT-PCR）分析IL-33和胎球蛋白A的基因表达。PF中IL-33蛋白水平显著高于血浆（PF：57.09 ng/L；血浆：50.15 ng/L；p<0.05）。同样，与血浆相比，PF中胎球蛋白A蛋白水平显著升高（PF：1060.53 mg/L；血浆：725.85 mg/L；p<0.05）。然而，血浆中IL-33和胎球蛋白A的基因表达水平（ΔCt值）显著高于PF（p<0.05）。血浆和PF中的CK-18蛋白水平相当（p>0.05）。在PF中，CK-18与IL-33之间（r=0.127，p<0.001）以及CK-18与胎球蛋白A之间（r=0.096，p<0.001）观察到强正相关。预计PF中的IL-33、胎球蛋白A和CK-18水平有可能用作CAD的生物标志物来源。虽然采集PF样本需要侵入性操作，但PF与心脏组织的接近性使其成为了解心脏病理生理学的宝贵来源。这些发现突出了PF生物标志物在CAD患者中的潜在诊断和治疗效用。
